Nature4y
Developing a pegfilgrastim biosimilar to increase patient access to cancer care
B12019 and Neulasta are formulations of pegfilgrastim, a pegylated form of the granulocyte colony-stimulating factor analog filgrastim, which mitigates the negative effects of chemotherapy on the ...
pharmaphorum1d
Amgen faces first Neulasta biosimilar rival as FDA approves Mylan drug
Neulasta brought in $4.5 billion for Amgen last year and now Mylan will be hoping its Fulphila (pegfilgrastim-jmdb) biosimilar can grab market share from it by offering a more cost-effective ...
Morningstar18d
Kashiv BioSciences, LLC Obtains Marketing Authorization for Pegfilgrastim Injection from Health Canada
Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that Health Canada has granted marketing authorization for its Pegfilgrastim Injection, enabling its commercial launch ...
pharmaphorum3y
BeyondSpring faces a tough winter as FDA rejects its lead drug
The company had sought approval of plinabulin for the prevention of chemotherapy-induced neutropenia (CIN) in combination with granulocyte colony-stimulating factor (G-CSF) drug pegfilgrastim ...
Financial Post18d
Kashiv BioSciences, LLC Obtains Marketing Authorization for Pegfilgrastim Injection from Health Canada
PISCATAWAY, N.J. — Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that Health Canada has granted marketing authorization for its Pegfilgrastim Injection, enabling its commercial ...